DexCom announced it will begin rolling out its fully reimagined Stelo app experience in the United States starting in July, with plans to expand the platform to the United Kingdom, Australia, New Zealand and South Korea later this year and further expansion continuing into 2027. The updated app, available for Apple iPhone and Android users, aims to make glucose insights more accessible and actionable for individuals seeking to understand their metabolic health. The company also highlighted the recent FDA clearance of Stelo for pediatric use, expanding its indication to include children aged 2 years and older who are not using insulin. DexCom shares lost 0.2% following the announcement, and the stock has gained 3.8% year to date against an 18.3% decline for the industry.
Globus Medical
Intuitive Surgical IncDexCom IncDexCom announced a redesigned Stelo app launch and international expansion, plus FDA clearance for pediatric use
